The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients
Recruiting now
Conditions studied: Ischemic Stroke
In brief
The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.
Key facts
- Study ID
- NCT03571763
- Run by
- General Hospital of Shenyang Military Region
- People needed
- 1875
- Starts
- 2018-08-01
- Expected to finish
- 2026-12-30
- Last updated by the study team
- 2026-04-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient age ≥18 years;
- Acute ischemic stroke patient confirmed by imaging;
- Time of onset: within 3 months;
- Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke;
- Baseline SWI sequence must have at least one CMB ;
- NIHSS≤10
You may not qualify if…
- MRI contraindication;
- Hemorrhagic transformation after acute Ischemic stroke;
- Contraindication for antiplatelet or anticoagulation therapy;
- Severe head trauma or intracranial hemorrhage occurred in the past six months;
- obvious coagulopathy;
- Other intracranial lesions associated with (such as tumor, cerebral vascular malformation);
- other unqualified patients judged by the investigator
Where it is running
- General Hospital of ShenYang Military Region — Shenyang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.